FOR IMMEDIATE RELEASE
JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications
Study to Explore JAN101’s Potential to Treat Ischemia1 and Endothelial dysfunction2 in COVID-19 patients.
LAS VEGAS, Aug. 6, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has entered into an agreement with CATO SMS, a world-leading, international regulatory and clinical contract research organization (CRO). CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients. In addition, JAN101 is expected to enter Phase 2b trials in early 2021 to treat Peripheral Artery Disease (PAD).
A recent study published in the New England Journal of Medicine3 indicates the possibility that the respiratory complications from COVID-19 may originate from restrictions and damage to the vascular system and endothelial cell dysfunction. The implication is that the endothelial cells that line the blood vessels are severely compromised and limit the body’s ability to carry oxygen to major organs in the body, including the lungs. Previous JAN101 clinical studies have shown promise in repairing and restoring vascular function with minimal adverse events, which may potentially prove to be beneficial to COVID-19 patients.
“If COVID-19 is, in fact, a vascular disease that attacks endothelial cells restricting the ability of cells to deliver oxygen to vital organs, our sodium nitrite tablets could potentially offer a safe and effective treatment for that aspect of the disease,” said Tony Giordano, PhD, JanOne’s chief scientific officer. “By mitigating severe organ and tissue damage, JAN101 can potentially have a significant impact on the long-term health of these patients.”
CATO SMS will work directly with the JanOne leadership team and scientific advisory board to execute submission of an investigator-initiated IND for use of JAN101 as a potential treatment for certain aspects of bodily damage created by COVID‑19. “We have all seen the devastating impacts of COVID-19 and the severe damage it appears to cause to vital organs that may be a result from an attack on the vascular system,” commented MerriBeth Adams, Senior Vice President, Regulatory Affairs at CATO SMS. “We are grateful for the opportunity to work with JanOne and to do our part to potentially bring such an important treatment to COVID-19 patients.”
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19, New England Journal of Medicine, July 9, 2020
In partnership with CATO SMS, JanOne is currently preparing an investigator-initiated IND package for the FDA, which it expects to submit in the coming month. If cleared to proceed by the FDA, clinical management of any ensuing research trials could start quickly and be conducted by Dr. Amol Soin, JanOne’s chief medical officer. “JAN101 has a unique approach to treating end organ damage that may result from COVID-19, which hopefully will help patients. I look forward to commencing human trials in Dayton, Ohio in the near future,” said Dr. Soin.
JanOne’s CEO Tony Isaac said, “Treatments for COVID-19 complications such as those JAN101 is looking to address are essential, and we believe our decision to engage CATO SMS’ expertise to guide us through the FDA’s regulatory process is the right choice.” In the future, JanOne looks forward to working with CATO SMS and the FDA to seek an emergency use authorization for JAN101 in COVID-19 patients.
Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In accordance with the safe harbor provisions of this Act, statements contained herein that look forward in time that include everything other than historical information, including statements relating to (i) JAN101’s expectation of when it will enter Phase 2b trials to treat PAD, (ii) whether JAN101 is beneficial to COVID-19 patients, (iii) whether JAN101 can offer a safe and effective treatment to COVID-19, (iv) whether JAN101 can treat vascular complications to potentially restore endothelial cell function in COVID-19 patients, and (v) the timing of the submission by the company of the IND package for the FDA. These forward-looking statements can be identified by terminology such as “will,” “aims,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. JanOne may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”) on Forms 10-K and 10-Q, Current Reports on Form 8-K, in its annual report to stockholders, in press releases, and other written materials and in oral statements made by its officers, directors or employees to third parties. There can be no assurance that such statements will prove to be accurate and there are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the company, including, but not limited to, plans and objectives of management for future operations or products, the market acceptance or future success of our products, and our future financial performance. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Annual Report on Form 10-K for the fiscal year ended December 28, 2019 (available at http://www.sec.gov). JanOne undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.
JanOne (NASDAQ: JAN) is focused on bringing medications to market to treat diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, ARCA Recycling and GeoTraq, both of which are undergoing review to determine appropriate strategic alternatives. For more information, visit janone.com
About CATO SMS
CATO SMS is a provider of specialized clinical research solutions. The company was formed when CATO Research LLC and Specialized Medical Services-oncology B.V. (SMS-oncology) merged in 2019. With more than 30 years of experience focusing on the needs of small and emerging biopharmaceutical companies, CATO SMS effectively designs and executes studies — from strategy to approval — in complex indications and modalities across a variety of therapeutic areas, with a proven center of excellence in oncology. CATO SMS’ regulatory, therapeutic, and operational expertise supports clients with achieving their goals and exceeding their expectations. Visit CATO-SMS.com for more information.
Investor Relations & Media Contact
1 (800) 400-2247